Abstract
Tyrosine kinase inhibitors potentiate anti-myeloma activity of proteasome inhibitor carfilzomib in resistant multiple myeloma cell lines and patient samples
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have